Clinical Trials
Study Title:
An Open Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein Barr Virus Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL 1)
|
For more information about the trial above please contact the study team:
Medical University of South Carolina
Principal Investigator, Irl Greenwell, at greenwe@musc.edu, or please call +1 843-792-4759.
Study Coordinator, Sarah Milligan, at millisar@musc.edu.
Trial opened at the following institutions: Medical University of South Carolina |